We observed higher antigen-specific T-cell proliferation in four and increased IFNγ production in five out of the five tested baseline PBMC samples when Nivolumab was present (Fig. 6C and D), indicating that PD-1 expression contributed to the immune suppression in patients with cervical cancer. This evidence concerns the gene PDCD1 and cervical carcinoma.